KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Nektar Therapeutics (NKTR) over the last 13 years, with Q3 2025 value amounting to $18.9 million.

  • Nektar Therapeutics' Shares Outstanding (Diluted Average) rose 3581.91% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 3581.91%. This contributed to the annual value of $205.7 million for FY2024, which is 824.21% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Shares Outstanding (Diluted Average) is $18.9 million, which was up 3581.91% from $14.1 million recorded in Q2 2025.
  • Nektar Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $210.9 million during Q1 2025, with a 5-year trough of $13.9 million in Q2 2024.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $186.8 million (2022), whereas its average is $153.2 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first crashed by 9267.36% in 2024, then skyrocketed by 3581.91% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $183.3 million in 2021, then increased by 2.09% to $187.1 million in 2022, then increased by 1.53% to $190.0 million in 2023, then increased by 8.24% to $205.7 million in 2024, then crashed by 90.79% to $18.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $18.9 million for Q3 2025, versus $14.1 million for Q2 2025 and $210.9 million for Q1 2025.